Biobanking For Medicine: Technology And Market 2013-2023

News provided by

Apr 30, 2013, 08:00 ET

NEW YORK, April 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biobanking For Medicine: Technology And Market 2013-2023
http://www.reportlinker.com/p0765582/Biobanking-For-Medicine-Technology-And-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

Report Details

Biobanks - what are their technological and commercial prospects?

See what the future holds for biobanking in human medicine. Visiongain's updated report gives you its revenue predictions to 2023. There you see sales data, technological trends, opportunities and financial prospects.

Our study shows you the potential of technologies, products and services for that archiving of medical biosamples. In that work you see forecasted sales at overall world market, submarket and national level. Discover what's likely to happen from 2013.

In biobanking, many opportunities remain, especially for pharmaceutical applications. In our work you discover which areas can most develop and prosper. Read on to scan crucial features of that industry, find what drives it, and see what its future market could be worth.

Forecasts and other analyses to help you find the best growth opportunities

In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. There you assess quantitative and qualitative analysis, business news, outlooks and developmental trends. You gain 47 tables, 44 charts and seven full research interviews.

Our work lets you investigate the most promising and lucrative aspects of biorepositories, biotrusts and biolibraries, helping you stay ahead in knowledge. That way, you reduce the risk of your missing out.

See, then, the future of preserving biosamples to benefit medicine. The following sections show what you discover there in our new report.

Find sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for three main biobanking submarkets:
• Human tissue samples
• Stem cells and related biorepository material
• Other biopreservation - including DNA, RNA and body fluids.

Our study breaks the human tissues segment into these further divisions, with forecasts to 2023:
• Commercial biorepositories - service-providing companies
• Public-sector storage facilities - hospitals, clinics, research institutes and universities.

For stem cell banking, our analysis breaks that segment into these divisions, with forecasts to 2023:
• Cord blood storage
• Other biological sample archives.

Our investigation also discusses what stimulates and restrains business for medical sample preservation. In our work you find dynamics of that healthcare industry and assess its potential sales, seeing what's likely to achieve the most success.

That study also divides its overall world revenue forecast into those for the main geographical markets.

What prospects for leading regions and countries?

Developments worldwide will influence the biobanking industry and market, especially rising demand for those services in emerging countries - particularly India and China.

In developed and developing countries there exist many opportunities for medical biosample archiving. Our work shows potentials there. You see prospects for supplying and using storage facilities in biopreservation. Also, you see opportunities for biomedical industries.

Our analyses thus show you individual revenue forecasts to 2023 for eleven national markets:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

There you discover progress and outlooks. That way you assess the industry's future - hear about developments and find their significance. Our work explains, exploring many issues.

What affects the biobanking industry and market?

Our study lets you assess trends and outlooks. There, you find discussions of issues and developments:
• Rising demand for biobanking resources
• Biobank networks and collaborations
• Pharma and biotech companies' in-house sample storage systems
• Distribution of biosample repositories worldwide and scale of operations
• Population- and disease-orientated biosample storage
• Ownership, funding and governmental support of the facilities
• Ethics, guidelines, regulations and legislation, including quality standards
• Standardisation of processes - challenges and opportunities.

Our work also discusses these aspects of the field:
• Uses to support drug and biomarker discovery
• Applications in medical research and drug development
• Collection and storage of genomic material, esp. DNA banking
• Human embryonic (hESC) and induced pluripotent (iPSCs) stem cells
• Cancer-cell banking services and applications in oncology
• Security and ownership of biospecimens
• Relevance of the processes to in vitro testing and molecular diagnostics.

The study covers supporting technology too:
• Automated liquid handling, frozen aliquotting and ultra-low temperature freezing
• Dry-state, room-temperature storage
• Energy conservation in biorepositories
• Consumables, RFID and tagging technologies
• Automated storage and retrieval systems for operational efficiency
• Software and laboratory information management systems (LIMS).

That way, you explore technological, economic, social and political (STEP) questions, assessing outlooks for that area of business. You also analyse the industry's strengths, weaknesses, opportunities and threats (SWOT).

Our report thus lets you assess the potential of biomedical storage and archiving to aid molecular, cellular and tissue-based research. See, then, what the future holds.

Leading companies and 2017 market value

What happens next? Our study predicts the world market for human medical biobanking will reach $24.4bn in 2017, and expand strongly to 2023.

Our report shows you what activities and organisations there hold potential. Its analyses cover these prominent companies:
• Tissue Solutions
• Asterand
• Biopta
• BioServe
• Cord Blood America
• Cryo-Cell International
• Cryo-Save.

Our work also analyses these participants, and discusses other companies:
• China Cord Blood Corporation
• LifebankUSA
• Stem Cell Authority
• ViaCord
• Biogenea
• StemLife
• Future Health Biobank
• NeoStem.

In our study you find 210 organisations mentioned. Also, you read seven interviews with authorities in the field. See who shapes it, discovering what they think, do and say.

Prospects for biobanking are strong, and from 2013 onwards there will arise many opportunities. Our work shows you its prospects, helping you stay ahead.

Eight ways Biobanking for Medicine: Technology and Market 2013-2023 helps you
To sum up, our investigation gives you the following knowledge:
• Revenues to 2023 for the world market for medical biobanks - you discover that industry's sales prospects
• Revenues to 2023 for 7 world-level submarkets - you discover the potential of its segments, finding the most promising areas for investments and revenues
• Forecasts to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see national sales potentials, finding the best regions for revenues and growth
• Profiles of 15 leading companies - you hear about strategies, capabilities, results and outlooks
• Interviews with leaders in the industry - you discover debates and opinions to help you stay ahead
• Competition and opportunities - you see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
• Analysis of what stimulates and restrains the industry and market - you assess challenges and strengths, helping you compete and gain advantages
• Prospects for established competitors and organisations seeking to enter the sector - you explore needs, practices and outlooks for future success.

You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.

Our knowledge costs only a tiny fraction of potential profits from your understanding and harnessing that market. See its growth potential and find what you can gain.

Ordering now lets you discover crucial predictions for 2013 onwards

Our investigation is for everyone needing analysis of the industry and market for biobanking. There you find data, trends, opportunities and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Table of Contents

1. Executive Summary
1.1 Main Findings of this Report
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outlines
1.2.2 On Assessing the Biobanking Industry and Market
1.3 Research and Analysis Methods
1.3.1 Human Tissue Banking Market
1.3.2 Stem Cell Banking Market

2. Introduction to Biobanking
2.1 Biobanking
2.1.1 Processes Involved in Biobanking
2.2 Biobanks: A Two-Fold Character
2.3 Key Features
2.4 Classification of Biobanks
2.4.1 Volunteer Groups
2.4.1.1 Population-Based Biobanks
2.4.1.2 Disease-Oriented Biobanks
2.4.2 Ownership or Funding Structure
2.5 Guidelines and Standards
2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research
2.5.2 Industry Standards for Biobanks
2.5.3 Biobanking Processes Governed by Guidelines
2.6 Laws and Regulations for Biobank-Based Research
2.6.1 HIPAA Amendments

3. Biobanking and the Pharmaceutical Industry
3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry
3.1.1 Research and Drug Development
3.1.1.1 Understanding Disease Pathways
3.1.1.2 Drug Discovery
3.1.1.3 Biomarker Discovery
3.1.2 Therapeutics
3.1.3 Clinical Trials
3.2 Biobanks Operated by Pharmaceutical Companies

4. The World Medical Biobanking Market, 2013-2023
4.1 The World Medical Biobanking Market in 2012
4.2 Revenue Forecast for the World Medical Biobanking Market, 2013-2023
4.3 Biobanking Networks
4.3.1 Biobanking Networks in Europe
4.3.1.1Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)
4.4 Commercial Biobanks: New Resources for Research
4.5 Growing Demand for Biobank Resources

5. The Human Tissue Banking Market to 2023
5.1 The Overall Human Tissue Banking Market, 2012-2023
5.1.1 The Human Tissue Banking Market in 2012
5.1.2 Human Tissue Banking: Market Forecast, 2013-2023
5.2 The Human Tissue Banking Market: Commercial vs. Public Sector
5.3 Revenue Forecast for the Human Tissue Banking Market by Type of Biobank, 2013-2023
5.3.1 Commercial Human Tissue Banks: Market Forecast, 2013-2023
5.3.2 Public Sector and Other Human Tissue Banks: Market Forecast, 2013-2023

6. The Stem Cell Banking Market to 2023
6.1 The Overall Stem Cell Banking Market, 2012-2023
6.1.1 The Stem Cell Banking Market in 2012
6.1.2 Stem Cell Banking: Market Forecast, 2013-2023
6.2 Stem Cell Banks for Research: High Growth Possible
6.3 Stem Cell Banking and its Submarkets
6.3.1 Umbilical Cord Blood Banking: A Key Submarket
6.3.1.1 Blood Banks: Private vs. Public
6.3.1.2 Umbilical Cord Banking: The Controversies
6.3.2 Submarkets of Stem Cell Banking: Revenue Forecasts, 2013-2023
6.3.2.1 Revenue Forecast for Private Cord Blood Banking Market, 2013-2023

7. Leading National Markets to 2023
7.1 Geographical Footprint
7.1.1 Biobanks in Europe
7.1.2 Biobanks in the US
7.1.3 Biobanks in Asia
7.2 Biobanking for Medicine: Leading National Markets in 2012
7.3 Leading National Markets: Forecasts to 2023
7.3.1 The US Medical Biobanking Market, 2012-2023
7.3.2 The Leading European Medical Biobanking Markets, 2012-2023
7.3.3 The Japanese Medical Biobanking Market, 2012-2023
7.3.4 The Chinese Medical Biobanking Market, 2012-2023
7.3.5 The Indian Medical Biobanking Market, 2012-2023
7.3.6 The Brazilian Medical Biobanking Market, 2012-2023
7.3.7 The Russian Medical Biobanking Market, 2012-2023

8. Biobanking Associated Market: Systems, Software, Consumables and Services Associated with Biobanking
8.1 Overview
8.2 Systems and Technologies
8.2.1 Automated Liquid Handling
8.2.2 Frozen Aliquotting: New Technology
8.3 Storage
8.3.1 Ultra-Low Temperature Freezing
8.3.2 Dry-State, Room-Temperature Storage
8.3.3 RFID and Tagging Technologies
8.3.4 Automated Storage and Retrieval Systems
8.4 Software
8.4.1 Laboratory Information Management System (LIMS)
8.4.1.1 LIMS Functions
8.5 Consumables
8.5.1 Addressing Sample Storage and Tracking Issues
8.6 Services

9. Leading Companies in the Market
9.1 Business Models of Companies in the Biobanking Market
9.2 Commercial Participants in the Human Tissue Banking Market
9.2.1 Tissue Solutions
9.2.1.1 Overview
9.2.1.2 Global Presence
9.2.1.3 Products and Services
9.2.1.3.1 Banked Samples
9.2.1.3.2 Prospective Samples
9.2.1.3.3 Fresh Samples
9.2.1.3.4 Freshly Isolated and Primary Cells
9.2.1.3.5 FDA/ EMEA Panel of Normal Tissues
9.2.1.3.6 Services
9.2.1.4 Strengths and Capabilities
9.2.1.5 Future Outlook
9.2.2 Asterand
9.2.2.1 Overview
9.2.2.2 Products and Services
9.2.2.2.1 XpressBANK
9.2.2.2.2 ProCURE
9.2.2.2.3 PhaseZERO
9.2.2.3 Asterand: Raised Barriers for New Market Entrants?
9.2.2.4 Geographical Distribution of Revenue
9.2.3 Biopta
9.2.3.1 Overview
9.2.3.2 Products and Services
9.2.3.2.1 Fresh Tissue Sample Procurement
9.2.3.2.2 Safety and Adverse Effects Testing
9.2.3.2.3 Efficacy Testing
9.2.3.2.4 ADME Testing
9.2.3.3 Future Outlook
9.2.4 BioServe
9.2.4.1 Overview
9.2.4.2 Products and Services
9.2.4.2.1 Global BioRepository
9.2.4.2.2 The BioServe Network
9.2.4.2.3 Prospective Sample Collection
9.2.4.2.4 DNA and RNA Extractions
9.2.4.2.5 Genotyping
9.2.4.2.6 Real-Time PCR
9.2.4.2.7 DNA Synthesis
9.2.4.3 Future Outlook
9.3 Prominent Organisations in the Umbilical Cord Blood Banking Market
9.3.1 Cord Blood America: Looking Towards the Emerging Markets
9.3.2 Cryo-Cell International: The First Cord Blood Bank
9.3.3 Cryo-Save
9.3.4 China Cord Blood Corp
9.3.5 LifebankUSA: Placenta-Cord Banking
9.3.6 Stem Cell Authority: Exclusive Stem Cells
9.3.7 ViaCord: 300,000 Blood Units in Storage
9.4 Prominent Organisations in the Comprehensive Stem Cell Banking Market
9.4.1 Biogenea
9.4.2 StemLife
9.4.3 Future Health Biobank
9.4.4 NeoStem

10. Qualitative Analysis of the Biobanking Sector
10.1 Growing Demand for Biobank Resources
10.2 Industry Trends
10.2.1Automated Biobanking
10.2.1.1 Increased Uptake in Laboratory Information Management Systems (LIMS) in Biobanking
10.2.2 Creation of National Biobanks
10.2.3 Green Banking - Becoming More Energy Efficient
10.3 Strengths of the Biobanking Market, 2013
10.3.1 Potential to Change the Field of Medicine
10.3.2 Wealth of Information for Genetic Research
10.3.3 Governmental Support for Biobanking
10.4 Weaknesses of the Biobanking Market, 2013
10.4.1 A Fragmented Market
10.4.2 Lack of Standardisation
10.4.3 Quality Concerns for Some Existing Biospecimen Collections
10.5 Opportunities in the Biobanking Market, 2013-2023
10.5.1 Biobank Specimens in Genome-Wide Association Studies (GWAS)
10.5.2 Biobank Specimens in Preclinical Research
10.5.3 The Increasing Focus on Personalised Medicine
10.6 Threats in the Biobanking Market, 2013-2023
10.6.1 Limitations Surrounding Informed Consent
10.6.2 Biobanks: No Guarantee of Funding
10.6.3 Confidentiality and Security Concerns
10.6.4 Ownership of Biospecimens
10.7 Social, Technological, Economic and Political Issues Influencing the Biobanking Market

11. Research Interviews from Our Survey
11.1 Interview with Dr David Bunton, CEO and Co-Founder, Biopta Ltd.
11.1.1 On the Use of Human Tissue Samples by Biopharmaceutical Companies
11.1.2 Human Tissue vs. Stem Cells
11.1.3 On the Technology used in Biobanks
11.1.4 On the Future of the Biobanking Market
11.2 Interview with Dr Michael Leek, Commercial Operations Director, Pharmacells
11.2.1 On the Recent Increase in Stem Cell Banking Activity
11.2.2 On the Services of Pharmacells
11.2.3 On Adult Stem Cell Banking versus Umbilical Cord Blood Banking
11.2.4 On Challenges Facing the Stem Cell Banking Market
11.2.5 On the Technology Used by Pharmacells
11.2.6 On the Future of the Market
11.3 Interview with Dr Tetsuro Wakatsuki, Chief Scientific Officer, InvivoSciences Inc.
11.3.1 On the Services Provided by InvivoSciences
11.3.2 On the Future of this Biobanking-Associated Market
11.4 Interview with Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions
11.4.1On the Use of Biobank Samples in the Pharmaceutical Industry
11.4.2 On Commercial Aspects of Biobanking
11.4.3 On the Business of Tissue Solutions
11.4.4 On the Attractiveness of Human Tissue Banking
11.4.5 On the Future of the Biobanking Market
11.5 Interview with Dr Angel García Martín, Director, Inbiomed
11.5.1 On the Importance of Biobanking in the Pharmaceutical Industry
11.5.2 On the Use of Technology in Biobanking
11.5.3 On Increased Recognition of Biobanking Harmonisation of Samples
11.5.4 On the Use of Biobanks by the Pharmaceutical Industry
11.5.5 On Private Biobanks and Scale of Operations
11.5.6 Commercial and Public Biobanking and Legislation
11.5.7 On the Most Attractive Segment in Commercial Biobanking
11.5.8 On the Future of Biobanking: Drivers and Challenges
11.6 Interview with Dr Piet Smet, Director, Business Development, BioStorage Technologies
11.6.1 On Defining Biorepositories and Biobanks
11.6.2 On the Services of BioStorage
11.6.3 On Main Customers for BioStorage
11.6.4 On the Importance of Biorepositories in Research and Industry
11.6.5 On Technology Use in Biobanks
11.6.6 On Increased Recognition of Biobanking and Harmonisation of Samples
11.6.7 On the Use of Biobanks by the Pharmaceutical Industry
11.6.8 On Private Biobanks and Scale of Operations
11.6.9 On Commercial and Public Biobanking and Legislation
11.6.10 On the Most Attractive Segment in Commercial Biobanking
11.6.11 On Biobanking in 2020
11.6.12 On Drivers and Challenges in the Sector
11.7 Interview with Dr Tom Hoksbergen, Marketing and Sales, SampleNavigator Laboratory Automation Systems
11.7.1 On the Services of SampleNavigator
11.7.2 On Main Customers for SampleNavigator
11.7.3 On the Importance of Biorepositories in Research and Industry
11.7.4 On Technology Use in Biobanks
11.7.5 On Increased Recognition of Biobanking and Harmonisation of Samples
11.7.6 On the Use of Biobanks by the Pharmaceutical Industry
11.7.7 On Commercial Biorepositories/ Banks and Scale of Operations
11.7.8 On Commercial and Public Biobanking
11.7.9 On the Most Attractive Segment in Commercial Biobanking
11.7.10 On Biobanking in 2020
11.7.11 On Drivers and Challenges in the Sector

12. Conclusions
12.1 World Biobanking Market Overview to 2023
12.2 The Leading National Markets
12.3 Commercial Drivers of the Biobanking Market
12.4 The Sector has Marked Challenges, but Many Opportunities for Growth

List of Tables

Table 2.1 Prominent Population-Based Biobanks, 2013
Table 2.2 Prominent Disease-Based Biobanks, 2013
Table 2.3 Guidelines and Recommendations for Biobanks, 2013
Table 2.4 Laws and Regulations for Biobank-Based Research, Consent Requirements and Privacy/ Data Protection, 2013
Table 3.1 Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2013
Table 4.1 The World Medical Biobanking Market: Product Submarket Revenue, 2012
Table 4.2 World Medical Biobanking Market: Revenue Forecasts for Overall Market and Submarkets, 2012-2023
Table 5.1 Human Tissue Banking: Revenue Forecast, 2012-2023
Table 5.2 Human Tissue Banking Market by Type of Biobank, 2012
Table 5.3 Human Tissue Banking: Revenue Forecast by Type of Biobank, 2012-2023
Table 5.4 Commercial Tissue Biobanking: Revenue Forecast, 2012-2023
Table 5.5 Public Sector and Other Tissue Banks: Revenue Forecast, 2012-2023
Table 6.1 Stem Cell Banking: Overall Revenue Forecast, 2012-2023
Table 6.2 Prominent Stem Cell Banks Serving the Research Community
Table 6.3 Stem Cell Banking by Submarket, 2012
Table 6.4 Reported Fees of Various Private Cord Blood Banks
Table 6.5 Stem Cell Banking: Revenue Forecasts by Submarket, 2012-2023
Table 6.6 Revenue Forecast for the Private Cord Blood Banking Market, 2012-2023
Table 7.1 Estimated Number of Biobanks in Europe by Country, 2013
Table 7.2 The Leading National Biobanking Markets, 2012
Table 7.3 Leading National Markets: Revenue Forecasts, 2012-2023
Table 7.4 The US Biobanking Market: Revenue Forecast, 2012-2023
Table 7.5 The EU5 Biobanking Markets: Revenue Forecasts, 2012-2023
Table 7.6 The Japanese Biobanking Market: Revenue Forecast, 2012-2023
Table 7.7 The Chinese Biobanking Market: Revenue Forecast, 2012-2023
Table 7.8 The Indian Biobanking Market: Revenue Forecast, 2012-2023
Table 7.9 The Brazilian Biobanking Market: Revenue Forecast, 2012-2023
Table 7.10 The Russian Biobanking Market: Revenue Forecast, 2012-2023
Table 8.1 Prominent Companies Providing Automated Liquid Handling Technology, 2013
Table 8.2 Prominent Companies Providing Ultra-Low Temperature Freezers, 2013
Table 8.3 Prominent Manufacturers of Automated Biobanking Systems, 2013
Table 8.4 Major Vendors in the LIMS Market, 2013
Table 8.5 Prominent Consumables Suppliers for Biobanking, 2013
Table 8.6 Prominent Biorepository Service Providers, 2013
Table 9.1 Prominent Commercial Biobanks, 2013
Table 9.2 Asterand: Revenue by Geographical Area, 2011
Table 9.3 Prominent Companies in the Cord Blood Banking Market, 2013
Table 9.4 Cryo-Cell International Revenue, 2010-2012
Table 9.5 Cryo-Save: Geographical Breakdown of Revenue, 2010-2011
Table 9.6 China Cord Blood Corp: Revenue, 2011 and 2012
Table 9.7 Prominent Companies in the Extended Stem Cell Banking Market, 2013
Table 9.8 StemLife: Revenue, 9 Months to September, 2011 and 2012
Table 9.9 NeoStem: Revenue, 9 Months to 30th September, 2011 and 2012
Table 10.1 The Biobanking Market: Strengths and Weaknesses, 2013
Table 10.2 Biobanking for Medicine: Opportunities and Threats, 2013-2023
Table 10.3 Social, Technological, Economic and Political Issues Influencing the Biobanking Market (STEP Analysis), 2013
Table 12.1 The World Biobanking Market: Revenue Forecast, 2012-2023

List of Figures

Figure 2.1 Main Processes Involved in Biobanking, 2013
Figure 2.2 Classification of Biobanks, 2013
Figure 3.1 Biobanking and Pharmaceutical Development, 2013
Figure 4.1 Market Shares by Product Submarket, 2012
Figure 4.2 Market Shares by Product Submarket, 2023
Figure 4.3 Overall Medical Biobanking Revenue Forecast, 2012-2023
Figure 4.4 The World Biobanking Market: Drivers and Restraints, 2013-2023
Figure 5.1 Human Tissue Banking: Revenue Forecast, 2012-2023
Figure 5.2 Human Tissue Banking: Market Drivers and Restraints, 2013-2023
Figure 5.3 Human Tissue Banking: Market Shares by Type of Biobank, 2012
Figure 5.4 Human Tissue Banking: Revenue Forecasts by Type of Biobank, 2012-2023
Figure 5.5 Commercial Tissue Biobanking Market: Revenue Forecast, 2012-2023
Figure 5.6 Human Tissue Banking: Market Shares by Type of Biobank, 2023
Figure 5.7 Public Sector and Other Tissue Banks: Revenue Forecast, 2012-2023
Figure 6.1 Stem Cell Banking: Overall Revenue Forecast, 2012-2023
Figure 6.2 Stem Cell Banking: Market Drivers and Restraints, 2013-2023
Figure 6.3 Stem Cell Banking: Market Shares by Submarket, 2012
Figure 6.4 Reported Twenty-Year Storage Costs at Various Cord Blood Banks
Figure 6.5 Stem Cell Banking: Revenue Forecasts by Submarket, 2012-2023
Figure 6.6 Private Cord Blood Banking: Revenue Forecast, 2012-2023
Figure 6.7 Private Cord Blood Banking: Market Drivers and Restraints, 2013-2023
Figure 7.1 Biobanking for Medicine: Leading National Market Shares, 2012
Figure 7.2 Biobanking for Medicine: Leading National Market Shares, 2023
Figure 7.3 The US Biobanking Market: Revenue Forecast, 2012-2023
Figure 7.4 The EU5 Biobanking Market: Revenue Forecast, 2012-2023
Figure 7.5 The Japanese Biobanking Market: Revenue Forecast, 2012-2023
Figure 7.6 The Chinese Biobanking Market: Revenue Forecast, 2012-2023
Figure 7.7 The Indian Biobanking Market: Revenue Forecast, 2012-2023
Figure 7.8 The Brazilian Biobanking Market: Revenue Forecast, 2012-2023
Figure 7.9 The Russian Biobanking Market: Revenue Forecast, 2012-2023
Figure 8.1 Biobanking: Applications and Users
Figure 8.2 The Function of LIMS
Figure 9.1 Business Model: Commercial Sourcing of Biological Samples
Figure 9.2 Business Model: Commercial Banking of Biological Samples
Figure 9.3 Asterand: Revenue Shares by Destination Region, 2011
Figure 9.4 Asterand: Revenue Shares by Origin Region, 2011
Figure 9.5 Cryo-Cell International: Revenue 9 Months to August, 2010-2012
Figure 9.6 Cryo-Save: Geographical Breakdown of Revenue, 2011
Figure 9.7 China Cord Blood Corp: Revenue and No. of Subscribers, 6 months to 30th September 2011-2012
Figure 9.8 StemLife: Revenue, 9 Months to September, 2011 and 2012
Figure 9.9 NeoStem: Revenue Shares by Business Segment, 2012
Figure 9.10 NeoStem: Processing and Storage Services Revenue, 9 Months to 30th September, 2011 and 2012
Figure 12.1 Biobanking: Revenue Forecasts by Submarket, 2012-2023
Figure 12.2 National Biobanking Market Revenue Projections: 2012, 2017 and 2023

Companies Listed

Abbott Laboratories
Abcellute
Adnexus Therapeutics
AKH Biobank
Allied Minds Inc.
AlloSource
American Type Culture Collection (ATCC)
Amgen
Amsterdam Medical Center
Analytical Biological Services Inc.
ARUP Laboratories
AssureImmune
Asterand
AstraZeneca
Australasian Biospecimen Network (ABN)
Autoscribe
AXM Pharma
BancoVida
Bayer
Beckman Coulter
Biobank Ireland
Biobank Japan
Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)
BioBanking Solutions
BioCells
BioFortis
Biogen Idec
Biogenea
BioLife Solutions
Biomatrica
Biopta
BioRep Srl
BioServe
BioStorage Technologies
Biovault Technical
Bluechiip Tracking Solutions
BrainNet Europe
Bristol-Myers Squibb
Brooks
Caliper LifeSciences
Canadian Partnership for Tomorrow
CART aGENE
Celgene
Cellular Dynamics
China Cord Blood Corp
Chinese Ministry of Health
CorCell
Cord Blood America
CordLife
Cordlife Singapore
Coriell Institute for Medical Research
Council of Europe (CoE)
Covance
Cryo-Cell International
Cryometrix
Cryo-Save
CryoXtract Instruments
Cureline
Cybrdi
Danubian Biobank Foundation
deCODE genetics
Deloitte
East-West Bio
Eli Lilly
EuroBioBank (EBB)
European Commission (EC)
European Health Risk Monitoring (EHRM)
European Medicines Agency (EMA)
European Research Infrastructure Consortium
European Union Group on Ethics (EGE)
European, Middle-Eastern and African Society for Biopreservation and Biobanking (ESBB)
Fisher BioServices
Flinders Technology Associates (FTA)
Fondazione I.R.C.C.S. I Istituto Neurologico C. Besta
Food and Drug Administration (US FDA)
Fundación Istituto Valenciano de Oncologia
Fundeni Clinical Institute
Future Health Biobank
GC Biotech
GE Healthcare
Genentech
Generation Scotland
Genethon DNA and Cell Bank
Genome Quebec Biobank
GenVault
German Dementia Competence Network
Glasgow Caledonian University
GlaxoSmithKline (GSK)
H. Lee Moffitt Cancer Center and Research Institute
Hamilton Storage Technologies
Harvard University Medical School
Human Tissue Authority
Hungarian Biobank
HUNT Norway
ILS Bio LLC
Inbiobank
Inbiomed
Indivumed
Institut National de la Santé et de la Recherche Médicale (INSERM)
IntegenX
International Agency for Research on Cancer (IARC)
International Air Transport Association (IATA)
International Organization for Standardization (ISO)
International Society for Biological and Environmental Repositories (ISBER)
International Stem Cell Corporation
InvivoSciences
Kaiser Permanente
KORA-gen
LabVantage Solutions
LabWare
Latvia Biobank
Leiden University Medical Center
Life Cell
Life R.F.
LifebankUSA
LifeCell
LifeGene
LifeLines Biobank
Malaysian Cohort Project
Malmö Microbiology Biobank
Matrical Bioscience
Medical Research Council
Medical University of Gdansk
Merck & Co.
Merck Serono
Micronic
Millennium (Takeda Oncology Company)
MSD
NASA
National Cancer Institute (NCI)
National DNA Bank
National Institute of Environmental Health
National Institutes of Health (NIH)
National Research Ethics Service (NRES)
Necker DNA Bank
NeoStem
Neuromuscular Tissue Bank
New Brunswick Scientific
NEXUS Biosystems
Northeastern University
Northwest Regional Development Agency
Nova Biostorage
Novare Bio-Logistics
Novartis
NUgene Project
Ocimum Biosolutions
Office of Biorepositories and Biospecimen Research (OBBR)
OnCore UK
Organisation for Economic Co-operation and Development (OECD)
OriGene
Pacific BioMaterial Management
Panasonic Biomedical
PathServe
Perkin-Elmer Corporation
PerkinElmer Genetics
Pfizer
Pharmacells
Pop-Gen National Cohort
PrecisionMed
ProMedDx
ProteoGenex
Qiagen
RAND Corporation
Regenetech
REMP
Roche
RTS Life Science
SampleNavigator Laboratory Automation Systems
Saneron CCEL Therapeutics
Sanofi
Seattle Genetics
Sejtbank
SeqWright DNA Technology Services
Shandong Cord Blood Bank
Singapore Tissue Network
Sorenson Molecular Genealogy Foundation (SMGF)
Stanford University
StarLIMS
Stem Cell Authority
Stem Cells for Safer Medicine (SC4SM)
Stemgent
StemLife
Stemride International
Taizhou Biobank
Tecan
The Automation Partnership
The Centre for Integrated Genomic Medical Research, The University of Manchester
The Estonian Biobank
The Icelandic Database
Thermo Scientific
Tissue Bank Cryo Center Bulgaria
Tissue Solutions
Titan Pharmaceuticals
Trinity Biobank
Tumorothèque Necker-Enfants Malades
UK Biobank
UK Blood Service Collection
UK Stem Cell Bank
UmanGenomics
Umeå University
United Nations (UN)
University Hospital Angers
University Medical Center Gent
University of Massachusetts Stem Cell Bank
University of Milan
University of Tuebingen
US Biomax
ViaCell
ViaCord
VidaPlus
Wellcome Trust
Western Australian Genome Health Project
Wheaton Science International
Wisconsin International Stem Cell (WISC) Bank
World Health Organization (WHO)
Zhejiang Lukou Biotechnology Co.
Zhengzhou Feilong Medical Equipment Co.